NICE publishes draft guidance on abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy for consultation

In DRAFT guidance, NICE does not recommend abemaciclib plus fulvestrant for treating hormone receptor +ve, HER2 -ve advanced breast cancer in adults who have had endocrine therapy, because of uncertainties in the evidence and cost-effectiveness estimates above the usual threshold

National Institute for Health and Care Excellence